Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C, et al. Lancet. 2019;394(10209):1638-1650.
Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial.
Bachert C, et al. JAMA. 2016;315(5):469-479.
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Gevaert P, et al. J Allergy Clin Immunol. 2020;S0091-6749(20)30752-1. [E-pub ahead of print.]
Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology.
Dietz de Loos D, et al. J Allergy Clin Immunol. 2019;143(3):1207-1214.
Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps.
Bhattacharyya N, et al. Laryngoscope. 2019:129(9):1969-1975.
Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology.
Akdis CA, et al. J Allergy Clin Immunol. 2013;131(6):1479-1490.
Clinical research needs for the management of chronic rhinosinusitis with nasal polyps in the new era of biologics: a National Institute of Allergy and Infectious Diseases workshop.
Naclerio R, et al. J Allergy Clin Immunol Pract. 2020;8(5):1532-1549.
Biologics for chronic rhinosinusitis with nasal polyps.
Bachert C et al. Allergy Clin Immunol. 2020 ;145(3):725-739.
A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps.
Kern RC, et al. Int Forum Allergy Rhinol. 2018;8(4):471-481.
NAVIGATE II: randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis.
Leopold DA, et al. J Allergy Clin Immunol. 2019;143(1):126-134.
Current trends in topical therapies for chronic rhinosinusitis: update and literature review.
Varshney R, Lee JT. Expert Opin Drug Deliv. 2017;14(2):257-271.
Efficacy of fluticasone exhalation delivery system in the management of chronic rhinosinusitis: what is the evidence?
Kuan EC, et al. Int Forum Allergy Rhinol. 2019;9(S1):S16-S21.
Clinical Practice Guidelines
American Thoracic Society —An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications.
Dweik RA, et al. Am J Respir Crit Care Med. 2011;184(5):602-615.
International Consensus Statement on Allergy and Rhinology: Rhinosinusitis.
Orlandi RR, et al. Int Forum Allergy Rhinol. 2016;6(suppl 1):S22-S209.
American Academy of Otolaryngology-Head and Neck Surgery—Clinical practice guideline (update): adult sinusitis.
Rosenfeld RM, et al. Otolaryngol Head Neck Surg. 2015;152(suppl 2):S1-S39.
EUFOREA consensus on biologics for CRSwNP with or without asthma.
Fokkens WJ, et al. Allergy. 2019;74(12):2312-2319.
Chronic rhinosinusitis with nasal polyps.
Hopkins C. N Engl J Med. 2019;381(1):55-63.
Asthma and Allergy Foundation of America (AAFA)
AAFA is dedicated to improving the quality of life for people with asthma and allergic diseases including nasal polyps through education, advocacy, and research.
American Academy of Asthma, Allergy, and Immunology (AAAAI)
AAAAI is dedicated to the advancement of the knowledge and practice of allergy, asthma and immunology for optimal patient care.